In this work, we present the first study about the interactions of mitochondria-damaging Pt
(IV) prodrugs with cytochrome c. We synthesized a cisplatin-based Pt (IV) prodrug bearing a …

Platinum (IV) complexes are prodrugs of cisplatin with multiple potential advantages over
platinum (II) drugs. Mitochondria play pivotal roles in producing energy and inducing death …

Mitochondria have emerged as important targets for cisplatin in cancer therapy. Apart from
cisplatin, anticancer Pt complexes based on similar scaffolds have also been developed to …

Mounting evidence suggests that impairment of mitochondrial DNA (mtDNA), an important
element in the response of mitochondrial biological function but more susceptible to damage …

Cisplatin (CDDP) was considered as the milestone anticancer agent for the cancer
treatment, however, the side effects were also a huge threat to human health. Pt (IV) prodrug …

Cancer cells maintain normal mitochondrial glutathione as one of the defense mechanisms
to inhibit mitochondrial membrane polarization and hence apoptosis. A combinational …

Mitochondria as one of potential anticancer target, alternatively damaging mtDNA other than
nDNA is a potential method for platinum-based anticancer drugs to overcome cisplatin …

Platinum-based anticancer drugs are one of the most widely used anticancer
chemotherapeutics in oncology. Lonidamine (LND) could increase the response of human …

A mitochondria targeting dual‐action platinumIV prodrug exhibits high anticancer activity in
triple negative breast cancer cells. The complex intervenes in several cellular processes …

The mitochondrion is an important intracellular organelle for drug targeting due to its key
roles and functions in cellular proliferation and death. In the last few decades, several …